Abstract
In the latest decision in the long-running ‘pregabalin’ litigation, the Patents Court has refused to vary an interim injunction restraining Sandoz from proceeding with the launch of its full label generic pregabalin product, thereby maintaining protection for Warner-Lambert’s second medical use patent.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have